Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Fierce Health vs Omzo

Fierce Health
Graded #411

Higher grade

vs+2.3999999999999986
Omzo
Graded #459

Lower grade

The verdict

Fierce Health takes it — 56.6/100 to 54.2/100.

Fierce Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fierce Health is a direct-to-consumer telehealth brand selling compounded semaglutide and tirzepatide in both standard and microdose programs, alongside a longevity catalog.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOmzo +12
33
45
Dose & formulationFierce Health +37
77
40
Clinical oversightOmzo +14
62
76
Labs & monitoringEven
52
52
FulfillmentFierce Health +12
75
63
Contract termsOmzo +8
47
55
Fierce Health · left barOmzo · right bar

The numbers

MetricFierce HealthOmzo
WeighScore56.6/10054.2/100
GradeCC
Scorecard rank#411#459
Semaglutide$297/mo (3-month plan, compounded)Not disclosed
Tirzepatide$497/mo (3-month plan, compounded)Not disclosed
Coverage30 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Fierce Health

Graded #411 · C

Strengths

  • 30-state service list spelled out in the Terms — buyers can verify eligibility before intake
  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer on every product page
  • Four GLP-1 programs (standard and microdose semaglutide and tirzepatide) — a broader ladder than peers
  • Microdose tier at $197/mo is one of the lower entry points we've seen

Where it loses points

  • No named 503A compounding pharmacy partner — only generic 'partner pharmacies' language
  • Operating LLC name not disclosed anywhere on the site
  • Tirzepatide weight-loss program ($497/mo) showing 'sold out or unavailable' across all plans at review time
  • Clinical provider network not named
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Omzo

Graded #459 · C

Strengths

  • Compounded GLP-1 (semaglutide and tirzepatide) with clinician guidance
  • Free, discreet delivery on all treatments
  • FSA/HSA eligible
  • Multi-pillar: also women's hormone, sexual health, hair, skin, and daily health

Where it loses points

  • Pricing not published on the site — shown only after the intake quiz
  • Compounding pharmacy partner not named (states only 'independent state-licensed')
  • States of operation not published
  • Not LegitScript-certified (no certification displayed)
  • Legal entity not named; governing law given only as 'the state in which Omzo operates'

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard